Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
MWN-AI** Summary
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a leading biopharmaceutical company focused on developing innovative cancer therapies, is set to announce its unaudited financial results for the full year 2025 on March 25, 2026, at 7:00 PM EDT. The announcement will be followed by a business update and a Q&A session with the company's management. Investors can participate in this event via an English-language webcast scheduled for March 26, 2026, at 8:00 AM EDT, as well as a Mandarin-language session later that same day.
Ascentage Pharma is known for its robust pipeline targeting critical proteins involved in apoptosis, particularly in cancer treatment. Its flagship product, Olverembatinib, is a pioneering BCR-ABL1 inhibitor approved in China for patients with chronic myeloid leukemia (CML) and has been included in the National Reimbursement Drug List (NRDL). The company is currently conducting pivotal Phase III trials for Olverembatinib in various CML subpopulations, alongside other trials, including POLARIS-1 and POLARIS-3, to explore its efficacy in additional cancer types.
Moreover, Ascentage's second product, Lisaftoclax, has received approval from China’s National Medical Products Administration (NMPA) for chronic lymphocytic leukemia/small lymphocytic lymphoma and is involved in multiple global Phase III trials assessing its combination with BTK inhibitors.
The company has fostered significant partnerships with major pharmaceutical entities like Takeda and AstraZeneca, bolstered by collaborations with prominent cancer research institutions. This extensive network supports Ascentage's mission to bring novel therapies to patients confronting serious unmet medical needs in oncology. Investors and analysts keen to follow the developments can engage through the upcoming webcasts and find more information on the company's website.
MWN-AI** Analysis
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is poised to release its full-year 2025 unaudited financial results on March 25, 2026. Investors should keenly watch for this report, as it will provide insights into the company’s financial health, pipeline advancements, and overall business strategy amidst a competitive biopharmaceutical landscape.
The company has made significant strides in oncology, particularly with its lead product, Olverembatinib, a third-generation BCR-ABL1 inhibitor, and Lisaftoclax, a Bcl-2 inhibitor. Both products have been well-received in China, with Olverembatinib being included in the National Reimbursement Drug List. The initiation of registrational Phase III trials for both drugs suggests strong confidence in their potential and may significantly influence future earnings.
During the upcoming earnings call, it's imperative for investors to listen for updates about the ongoing POLARIS studies and any preliminary data regarding efficacy and safety that could validate Ascentage’s drug candidates. The company’s evolving partnerships with industry leaders such as Takeda and Merck further cements its position and can enhance its R&D capabilities, making it an attractive prospect in the oncology space.
Moreover, the market is increasingly focused on innovative therapies targeting unmet medical needs, and Ascentage appears to be on the right track. However, investors should also consider risks associated with regulatory hurdles and competition.
In summary, upcoming financial results paired with potential positive news from clinical trials could catalyze share price movements. Investors should prepare for elevated volatility surrounding the release and consider positioning accordingly. Monitoring Ascentage Pharma's developments closely will be critical as it navigates this transformative phase in its operational trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in discovering, developing and commercializing novel, differentiated therapies to address unmet medical needs in cancer, today reported it will release its full year 2025 unaudited results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on March 25, 2026 / 7:00 am Hong Kong Time (HKT) on March 26, 2026.
Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company’s management team.
Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 10:00 pm EDT on March 25, 2026 / 10:00 am HKT on March 26, 2026. To access the Chinese language investor event or conference call, please register in advance here.
The English language investor webcast will be held at 8:00 am EDT / 8:00 pm HKT on March 26, 2026. To access the English language webcast, please register in advance here. The webcast replay for English language presentation will also be available on the News & Events page of the Ascentage Pharma website.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.
The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Investor Relations:
Yuly Chen, Senior Director of Investor Relations
Ascentage Pharma
Yuly.Chen@ascentage.com
+86 512 85557777
+1 (301) 792-565
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012
FAQ**
How does Ascentage Pharma Group International AAPG plan to leverage its partnerships with leading companies to enhance its R&D capabilities in combating unmet medical needs in cancer in both the U.S. and Chinese markets?
What strategies does Ascentage Pharma Group International AAPG have in place to address potential risks and uncertainties that could affect its financial performance in the biopharmaceutical sector?
Can you discuss the significance of the ongoing POLARIS-2, POLARIS-1, and POLARIS-3 clinical trials for Ascentage Pharma Group International AAPG, particularly in terms of market expectations and regulatory outcomes?
In what ways does Ascentage Pharma Group International AAPG's first novel third-generation BCR-ABL1 inhibitor impact its market position against competitors in the global oncology landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Ascentage Pharma Group International (NASDAQ: AAPG).
NASDAQ: AAPG
AAPG Trading
1.01% G/L:
$24.02 Last:
1,109 Volume:
$24.02 Open:
